Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Perna

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
The American Journal of Pathology|February 25, 2003
Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesisFabio Cianchi, Camillo Cortesini, Ornella Fantappiè, et al.
Molecular Cancer Therapeutics|November 24, 2006
Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cellsFabio Cianchi, Camillo Cortesini, Lucia Magnelli, et al.
Cell and Tissue Research|March 12, 2004
Apoptosis shifts to necrosis via intermediate types of cell death by a mechanism depending on c-myc and bcl-2 expressionLaura Papucci, Lucia Formigli, Nicola Schiavone, et al.
Oncology Research|August 24, 2006
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedulesAlessio Tempestini, Barbara Caciagli, Maria Morganti, et al.
International Journal of Surgery (London, England)|June 30, 2015
Robotic pylorus-preserving pancreaticoduodenectomy: Technical considerationsAmilcare Parisi, Jacopo Desiderio, Stefano Trastulli, et al.
Trials|July 27, 2020
Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088)Igor Monsellato, Elisabetta Garibaldi, Elisa Cassinotti, et al.
BMC Cancer|December 18, 2019
Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
BMC Cancer|February 19, 2020
Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
The American Journal of Pathology|February 25, 2003
Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesisFabio Cianchi, Camillo Cortesini, Ornella Fantappiè, et al.
Molecular Cancer Therapeutics|November 24, 2006
Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cellsFabio Cianchi, Camillo Cortesini, Lucia Magnelli, et al.
Cell and Tissue Research|March 12, 2004
Apoptosis shifts to necrosis via intermediate types of cell death by a mechanism depending on c-myc and bcl-2 expressionLaura Papucci, Lucia Formigli, Nicola Schiavone, et al.
Oncology Research|August 24, 2006
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedulesAlessio Tempestini, Barbara Caciagli, Maria Morganti, et al.
International Journal of Surgery (London, England)|June 30, 2015
Robotic pylorus-preserving pancreaticoduodenectomy: Technical considerationsAmilcare Parisi, Jacopo Desiderio, Stefano Trastulli, et al.
Trials|July 27, 2020
Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088)Igor Monsellato, Elisabetta Garibaldi, Elisa Cassinotti, et al.
BMC Cancer|December 18, 2019
Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
BMC Cancer|February 19, 2020
Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
Pageof 4